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LETTERS TO THE EDITORRegarding “Caution in signing nondisclosure
contracts”
The editorial by K. W. Johnston, “Caution in signing nondis-
closure contracts,” in the June issue of the Journal of Vascular
Surgery (J Vasc Surg 2004;39:1352-1353) deserves more atten-
tion and further emphasis. Dr Johnston rightly touched on the
heart of the problem in the management of data with industrial
partners. Two important issues are apparent: (1) ownership of the
data and (2) freedom of the principle investigator to publish the
data even if the result is negative.
Due to a recent review of the Lifeline Endovascular Registry, I
have first-hand experience in dealing with these 2 issues. According
to the current agreement with industrial partners, the Endovascu-
lar Registry has no ownership of the data it collects and is prohib-
ited from publishing device-specific results. The registry receives
data from manufacturers, and only aggregate results can be re-
ported. This technique of reporting composite data rather than
device-specific results opens the avenue to hide negative results of
certain brands in the registry. With this system, the misconduct by
Guidant would not have been detected because submission of the
data on the Ancure device is from Guidant and not from individual
surgeons. Drug industry–imposed restrictions on publication is
now being addressed by New York’s attorney general in a civil suit
against GlaxoSmithKline alleging that the company committed
fraud by concealing negative information about Paxil, a drug used
to treat depression. A New York Times editorial on the suit said it is
outrageous that any company should have the power to mislead
doctors and their patients by stressing only positive results and
hiding negative findings.1 Obviously, how to report on drug trials
has become a medical journal quandary. The American Medical
Association has called on the government to establish a database or
registry for tracking clinical trials from start to end. A group of 12
medical journals worldwide, including Journal of the American
Medical Association, New England Journal of Medicine, and Lan-
cet, is weighing a proposal that would require a drug trial to be
listed at its start in a public database or registry as a prerequisite to
its results being considered for publication.2 In response to the
public criticism, GlaxoSmithKline plans a public listing of drug
trials on a Web site, which would disclose pre- and post-marketing
data.3 Although details have to be worked out, the idea of a Web
site for public disclosure is certainly a step in the right direction.
What happened in drug trials may certainly be applicable to
device trials. The recent squabble between the Food and Drug
Administration and Medtronic Inc regarding a publication on
endovascular stent graft is a case in point.4 Claiming confidentiality
pertaining to proprietary information and the threat of legal action,
Medtronic Inc has successfully forced the Food and Drug Admin-
istration to withdraw an article entitled “Aneurysm-related mor-
tality rates in the US AneuRx clinical trial,” which had been
accepted for publication in Journal of Vascular Surgery. Clearly,
the issue of proprietary information and whether the public has a
right to see the information companies collect must be addressed
and resolved by the scientific community and regulatory agencies.
The editor of Journal of Vascular Surgery should take note of the
need for openness of data when a report on a device trial is being
reviewed for publication. The Lifeline Board is in the process of
addressing these issues with industrial partners and only time will
tell whether there will be resolution.
Vascular surgeons must actively participate in clinical trials,
but in the process of signing a nondisclosure contract, they are best
advised to follow the recommendations outlined by Johnston. We
must be vigilant of the physician-industry relationship, and free-
dom to publish results by the investigator must be preserved. Inthis changing world, no matter what, there is no substitute for the
dictum of “Patient first.”
James S.T. Yao, MD
Magerstadt Professor of Surgery
Division of Vascular Surgery, Department of Surgery
Feinberg School of Medicine
Northwestern University
Chicago, Ill
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Regarding “Withdrawal of article by the FDA after
objection from Medtronic”
With regard to your recent Special Communication (J Vasc
Surg 2004;40:209-10), we believe it is important that your readers
understand Medtronic’s actions.
Medtronic contested the publishing of a proposed Journal of
Vascular Surgery (JVS) article that referenced our AneuRx device
on 2 grounds. One, the proposed article (written by Food and
Drug Administration [FDA] employees) was inconsistent with the
conclusions of the FDA’s Public Health Notification, dated De-
cember 17, 2003. We contend that having 2 publications from the
FDA that contained different conclusions —could cause confusion
and negatively affect treatment selection and patient care. Two, the
authors of the proposed article did not seek Medtronic’s permis-
sion to use and disclose our confidential and proprietary data
before publication—a practice that is standard in the industry and
required both by the law and the FDA’s own internal guidelines.
Medtronic never questioned the statistics about the AneuRx
device in either the FDA’s December 2003 Public Health Notifi-
cation or the proposed JVS article. Like many leading vascular
surgeons, we questioned the comparison rates for open surgical
repair. Ultimately, the FDA acknowledged Medtronic’s concerns
and asked that the article be withdrawn from publication in JVS, a
fact that has been widely communicated both to the editors of JVS
(through a letter from Dr Daniel Schultz at the FDA) and to the
public in a Wall Street Journal article dated July 9, 2004. The Wall
Street Journal story reported that the FDA withdrew the article
because of concerns about the unauthorized use of Medtronic’s
confidential data, and because “the conclusions drawn in the article
. . .go beyond the information provided in the Public Health
Notification (and) the article does not reflect the FDA’s current
position regarding AneuRx-related mortality.”
Medtronic has released extensive clinical data on the AneuRx
device. Our data have been published in 2 clinical updates issued to
more than 2000 physicians in both 2003 and 2004. In addition, 2
Public Health Notifications have been issued by the FDA on
AneuRx, and 112 peer-reviewed articles have been published on
the performance of this life-saving device over the past 5 years. This
record is unparalleled by peers in our industry.835
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Public Health Notifications), combined with the experience of
more than 40,000 patients in the United States, confirm that
AneuRx is a safe, effective, and important treatment option for
adults with potentially deadly abdominal aortic aneurysms. As
reported in Medtronic’s 2004 clinical update, US clinical results
from a total of 1193 patients (using Kaplan-Meier analyses) at 5
years are as follows:
● freedom from rupture rate of 97.2%
● freedom from surgical conversion rate of 91.1%
● freedom from aneurysm-related death rate of 96.8%
● probability of survival rate, based on all-cause mortality, of
61.5%
Going forward, Medtronic will continue to act, as necessary,
to ensure that our proprietary clinical data are used appropriately
and interpreted properly in the public domain.
We thank those clinical researchers who have had the vision
and drive to develop new and less invasive therapies for abdominal
aortic aneurysms, and we remain committed to restoring health
and extending life for the thousands of patients with this life-
threatening disease.
Stephen N. Oesterle, MD
Senior Vice President of Medicine and Technology
Medtronic, Inc
Minneapolis, Minn
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Regarding “Ethics of boutique medical practice”
The article in the June issue of the Journal by Jones et al
entitled “Ethics of boutique medical practice” (J Vasc Surg 2004;
39:1354-5) raises timely and important ethical issues that physi-
cians and health care consumers need to analyze and confront. We
would like to address a number of points made in the article that
could serve as a further basis for discussion on providing this type
of care.
It is noteworthy that Jones alleges that “boutique practice
reduces medicine to a commodity, unacceptably diminishing pro-
fessionalism” (italics added). From an economic standpoint, a
commodity is a type of service or product that is undifferentiated
and can be readily replicated. Indeed, their ready availability is the
reason why most commodity services are very price-elastic and
therefore relatively inexpensive. Consumers are not willing to pay
higher prices for services that are easily copied and are not distin-
guished by the quality of the provider of such services (such as dry
cleaners). What physicians are attempting to do by providing
boutique medicine is to differentiate themselves in the marketplace
by providing perceived specialized services. Ethical or not, the
result is not medicine as a commodity; if anything, boutique
medicine provides a highly differentiated product and service that
lies far from the definition of an economic commodity.
Perhaps this differentiation is what leads Jones to suggest that
a boutique medical practice will result in a 2-tiered system of
medicine. Arguably, the US health care system is already multit-
iered, with an increasing number of underinsured health care
recipients (including Medicare recipients without supplemental
coverage) being added to the dichotomy of fully insured and
uninsured populations.1 Levels of care and access to appropriate
services correlate to some degree to the “tier”; boutique medicine
likely represents a fourth level of health care access. As Uwe
Reinhardt2 has noted, concierge medicine is not qualitatively
different from limiting insurance participation; it is just a creative
extension of limiting care by class to improve profits.
Finally, one must wonder about the economic feasibility of
providing boutique surgical services. These services, unlike those
provided in primary care, are quite episodic; a patient may, in fact,not need such services for decades. It seems highly unlikely that
patients would therefore pay a retainer for boutique surgical care.
Concierge care may in fact be unethical. It does not, however,
reduce medicine to a commodity and is fundamentally no different
from physicians’ refusal to participate in low-paying insurance
plans, such as Medicaid. Analysis of the ethics of a boutique
medical practice should lead providers and consumers to a reap-
praisal of the national US health care system. And at any rate,
concierge surgical care may be only of academic concern. Very
likely, there will not be much of a market for it.
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Reply
We thank Drs Akbari and Henochowicz for their comments
on our critique of boutique medical practice. Our criticisms of the
practice were based on a concept at the core of medical ethics, the
physician as the patient’s fiduciary. We argued that the commodity
typically sold in these premium-priced programs—special access to
the physician’s care—serves the economic self-interest of physi-
cians without offering any improvement in the quality of care to be
provided, and inevitably does so by making physician access more
difficult for the clinic’s patients who have not elected to pay the
premium for the first-class plan. Drs Akbari and Henochowicz
appear not to contest this formulation, and concentrate their
objections upon alternative definitions of the term commodity, for
which they provide a description of the sort normally associated
with economic discourse.
This objection involves a pair of significant and related errors.
The first is that economic definitions and values outweigh all other
considerations, but Drs Akbari and Henochowicz provide no
argument to support this view. With their first mistaken assump-
tion unsupported, the second is something of an inevitability: a
specious reductionism in the economic definition of “commodity”
to its differentiation, which overlooks the word’s historical sense.
“Commodity” shares its etymology with “accommodate” and,
curiously, “commode.” “A commodity was a convenience, then an
opportunity, then an advantage, then a thing to sell at an advan-
tage, merchandise.”1 The authoritative dictionaries variously de-
fine commodities as economic goods, articles of commerce, things
useful or valued subject to ready exchange or exploitation within a
market; or as a mass-produced unspecialized product, an economic
unit useful in manufacturing.
Drs. Akbari and Henochowicz’s contention that “from an
economic standpoint, a commodity is a type of service or product
which is undifferentiated and can be readily replicated” is true, but
